Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin resistance and concurrent relative insulin deficiency and glucagon dysregulation underlie T2D pathophysiology.33–35”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alterations in these mechanisms lead to an increased fasting glucose production and impaired hepatic glucose uptake, contributing to the pathogenesis of type 2 diabetes (T2D) [1].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
(1922) · PubMed · Cited by 753
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Research works printed but not linked: 10
- Banting, 1922, Can Med Assoc J., 12, 141
- Cherrington, 1978, Biochem Soc Symp., 43, 31
- Exton, 1970, Recent Prog Horm Res., 26, 411
- Cherrington, 1979, Am J Physiol., 236, E263
- Davis, 1985, Am J Physiol., 248, E463
- Wada, 1995, Am J Physiol., 268, E194
- Holste, 1997, Am J Physiol., 273, E488
- Baum, 1962, Diabetes., 11, 371
- Meda, 1981, C R Seances Acad Sci III., 293, 607
- Cherrinton AD. Control of glucose production in vivo by insulin and glucagon. In:Handbook of Physiology . Vol. 2. 2011:759–785. · DOI · Paper page
Cited by
Items 201–300 of 682
Reestablishment of Glucose Inhibition of Glucagon Secretion in Small Pseudoislets
Reissaus, C. A., & Piston, D. W. (2017) · Diabetes · doi:10.2337/db16-1291 · Cited by 46
Zhang, X., Jin, Y., Wu, Y., Zhang, C., Jin, D.-J., Zheng, Q., & Li, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-30823-w · Cited by 52
Endocrine Autoimmune Disease as a Fragility of Immune Surveillance against Hypersecreting Mutants
Kohanim, Y. K., Tendler, A., Mayo, A., Friedman, N., & Alon, U. S. (2019) · Immunity · doi:10.1016/j.immuni.2020.04.022 · Cited by 49
Combinatorial transcription factor profiles predict mature and functional human islet α and β cells
Shrestha, S., Saunders, D. C., Walker, J. T., Camuñas-Soler, J., Dai, X.-Q., Haliyur, R., Aramandla, R., Poffenberger, G., Prasad, N., Bottino, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151621 · Cited by 52
Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX
Wang, G., Liu, J., Chen, K., Xu, Y., Liu, B., Liao, J., Zhu, L., Hu, X., Li, J., Pu, Y. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05840-w · Cited by 49
Hepatic Gi signaling regulates whole-body glucose homeostasis
Rossi, M., Zhu, L., McMillin, S. M., Pydi, S. P., Jain, S., Wang, L., Cui, Y., Lee, R. J., Cohen, A. H., Kaneto, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94505 · Cited by 48
“https://jci.me/94505/pdf 7 4 6 jci.org Volume 128 Number 2 February 2018 Introduction Type 2 diabetes (T2D) has emerged as a major health problem worldwide (1).”
BackgroundInfluentialGlucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose
Zhang, Y., Han, C., Zhu, W., Yang, G., Peng, X., Mehta, S., Zhang, J., Chen, L., & Liu, Y. (2021) · Cells · doi:10.3390/cells10092495 · Cited by 50
“However, the more potent activation of GCGR by excessive glucagon may upset this intricate balance and lead to overall adverse and diabetogenic effects, such as inducing more glucose production in the liver, which participates in and contributes to the progression of T2D, as confirmed [43].”
BackgroundMetabolic Messengers: glucagon
MacDonald, P. E., & Rorsman, P. (2023) · Nature Metabolism · doi:10.1038/s42255-022-00725-3 · Cited by 43
Inhibiting or antagonizing glucagon: making progress in diabetes care
Lefèbvre, P. J., Paquot, N., & Scheen, A. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12480 · Cited by 44
“Disruption of this mechanism is proposed as a key factor in the pathogenesis of diabetes [21].”
BackgroundGPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia
Li, N. X., Brown, S. N., Kowalski, T. J., Wu, M. S., Yang, L. M., Dai, G., Petrov, A., Ding, Y., Dlugos, T., Wood, H. B., et al. (2018) · Diabetes · doi:10.2337/db18-0031 · Cited by 45
Baicalin regulates SirT1/STAT3 pathway and restrains excessive hepatic glucose production
Xu, J., Li, Y., Lou, M., Xia, W., Liu, Q., Xie, G., Liu, L., Liu, B., Yang, J., & Qin, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.018 · Cited by 45
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Adolphe, J. L., Silver, T. I., Childs, H., Drew, M. D., & Weber, L. P. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514001214 · Cited by 52
“It has been suggested that an insulinocentric view of glucose homeostasis is incomplete and that glucagon plays a vital role in the regulation of glucose metabolism((46,47)).”
BackgroundImpact of Pdx1‐associated chromatin modifiers on islet β‐cells
Spaeth, J. M., Walker, E. M., & Stein, R. W. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12730 · Cited by 45
“Consequently, glucagon and insulin oppose the action of one another and must be in perfect balance to maintain euglycaemia.(1) Diabetes mellitus arises when this balance is disrupted and improper insulin and/or glucagon release leads to impaired glucose homeostasis.”
BackgroundGcg CreERT2 knockin mice as a tool for genetic manipulation in pancreatic alpha cells
Shiota, C., Prasadan, K. L., Guo, P., Fusco, J. C., Xiao, X., & Gittes, G. K. (2017) · Diabetologia · doi:10.1007/s00125-017-4425-x · Cited by 46
“However, it has become evident that dysregulation of glucagon secretion by alpha cells also contributes to diabetes development and severity, indicating that alpha cells could also be a therapeutic target for better management of the disease [1, 2].”
Coccurello, R., Nazio, F., Rossi, C., Angelis, F. D., Vacca, V., Giacovazzo, G., Procacci, P., Magnaghi, V., Ciavardelli, D., & Marinelli, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208596 · Cited by 48
Aw, D. K. L., Sinha, R. A., Xie, S. Y., & Yen, P. M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.031 · Cited by 48
Lou, M., Li, J., Cheng, Y., Xiao, N., Ma, G., Li, P., Liu, B., Liu, Q., & Qi, L. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14758 · Cited by 47
“In spite of being required for glucose homeostasis in the fasting state, enhanced hepatic glucagon response and excessive HGP are responsible for hyperglycaemia in diabetes (Unger & Cherrington, 2012).”
BackgroundChoukem, S. P., Sobngwi, E., Boudou, P., Fetita, L.-S., Porcher, R., Ibrahim, F., Blondeau, B., Vexiau, P., Mauvais‐Jarvis, F., Calvo, F. M., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0798 · Cited by 47
“Hyperglucagonemia is well recognized as a metabolic feature of type 2 diabetes, even in well-controlled subjects, (27) suggesting that it participates in the pathophysiology of the disease (review in (29,30)).”
Gs-DREADD Knock-In Mice for Tissue-Specific, Temporal Stimulation of Cyclic AMP Signaling
Akhmedov, D., Mendoza‐Rodriguez, M. G., Rajendran, K., Rossi, M., Wess, J., & Berdeaux, R. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00584-16 · Cited by 45
“Hyperglucagonemia is thought to contribute to hyperglycemia in type 2 diabetes (60–63).”
Hepatic β-arrestin 2 is essential for maintaining euglycemia
Zhu, L., Rossi, M., Cui, Y., Lee, R. J., Sakamoto, W., Perry, N. A., Urs, N. M., Caron, M. G., Gurevich, V. V., Godlewski, G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92913 · Cited by 45
Bonnet-Serrano, F., Diedisheim, M., Mallone, R., & Larger, É. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191528 · Cited by 45
Warner, S. O., Yao, M. V., Cason, R. L., & Winnick, J. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00567 · Cited by 43
Functional implications of long non-coding RNAs in the pancreatic islets of Langerhans
Esguerra, J. L. S., & Eliasson, L. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00209 · Cited by 41
“…in ribonucleoprotein complexes, e.g., transcription or chromatin-modifying factors, acting in cis or in trans on the genome (Yang et al., 2014a), and (ii) as incidental by-products of a negative type of transcriptional regulation termed, “transcriptional interference” (Kornienko et al., 2013).”
BackgroundMulti-Omics Insights into Functional Alterations of the Liver in Insulin-Deficient Diabetes Mellitus
Backman, M., Flenkenthaler, F., Blutke, A., Dahlhoff, M., Ländström, E., Renner, S., Philippou‐Massier, J., Krebs, S., Rathkolb, B., Prehn, C. P., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2019.05.011 · Cited by 49
“com progressive loss of beta cells and the lacking paracrine control of glucagon secretion from neighboring alpha cells by insulin (reviewed in [40]).”
BackgroundInactivation of NF-κB2 (p52) restrains hepatic glucagon response via preserving PDE4B induction
Zhang, W., Pan, A., Zhang, X., Ying, A., Ma, G., Liu, B., Qi, L., Liu, Q., & Li, P. (2019) · Nature Communications · doi:10.1038/s41467-019-12351-x · Cited by 44
Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte
Habegger, K. M. (2022) · Diabetes · doi:10.2337/dbi22-0002 · Cited by 44
Elrick, M. M., Samson, W. K., Corbett, J. A., Salvatori, A. S., Stein, L. M., Kolar, G. R., Naatz, A., & Yosten, G. L. C. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00369.2014 · Cited by 45
TASK-1 Potassium Channels Limit Pancreatic α-Cell Calcium Influx and Glucagon Secretion
Dadi, P. K., Luo, B., Vierra, N. C., & Jacobson, D. A. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1321 · Cited by 40
Glucagon-induced extracellular cAMP regulates hepatic lipid metabolism
Lv, S., Qiu, X., Li, J., Liang, J., Li, W., Zhang, C., Zhang, Z., & Luan, B. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0649 · Cited by 42
“Glucagon and its receptor contributes to the establishment of hyperglycemia and insulin resistance (Unger & Cherrington 2012, Patarrao et al.”
BackgroundGlucagon’s effect on liver protein metabolism in vivo
Kraft, G., Coate, K. C., Winnick, J. J., Dardevet, D. P., Donahue, E. P., Cherrington, A. D., Williams, P. E., & Moore, M. C. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00045.2017 · Cited by 43
“Moreover, recent work (59) has highlighted the contribution of glucagon to diabetes mellitus and redefines the disease as a bihormonal or even a glucagonocentric disease, which further indicates the need for research on glucagon’s effects on metabolism.”
Self-citationLai, B. K., Chae, H., Gómez-Ruiz, A., Cheng, P., Gallo, P., Antoine, N., Beauloye, C., Jonas, J., Seghers, V. J., Seino, S., et al. (2018) · Diabetes · doi:10.2337/db17-0880 · Cited by 44
“The discovery that hyperglucagonemia (1-3) contributes to diabetes has sparked much interest in understanding the physiology of pancreatic α-cells.”
BackgroundPedersen, J. S., Rygg, M. O., Kristiansen, V. B., Olsen, B. H., Serizawa, R. R., Holst, J. J., Madsbad, S., Gluud, L. L., Bendtsen, F., & Wewer Albrechtsen, N. J. (2020) · Hepatology Communications · doi:10.1002/hep4.1562 · Cited by 39
“Fa st in g in su lin (p m ol /L ) 10 6 (8 516 3) 14 1 (9 918 3) 14 7 (1 21 -2 52 ) 64 (4 796 ) ‡ ,§ 61 (4 174 ) † 54 (4 294 ) 70 (5 813 7) §”
BackgroundInfluentialIntercellular Communication in the Islet of Langerhans in Health and Disease
Ng, X. W., Chung, Y. H., & Piston, D. W. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200026 · Cited by 43
Soedling, H. M., Hodson, D. J., Adriaenssens, A. E., Gribble, F. M., Reimann, F., Trapp, S., & Rutter, G. A. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.06.007 · Cited by 44
“Defects in the release or actions of either hormone can thus contribute to the disease [3].”
BackgroundKazda, C. M., Frias, J., Foga, I., Cui, X., Guzman, C. B., Garhyan, P., Heilmann, C., Yang, J. A., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12904 · Cited by 39
Edelman, S. V., & Blose, J. S. (2014) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721714529608 · Cited by 39
“Individuals with T1DM or advanced T2DM have deficient β-cell suppression of α-cell glucagon secretion, resulting in exaggerated glucagon responses to meals.(28,29)”
BackgroundIatrogenic hyperinsulinemia in type 1 diabetes: Its effect on atherogenic risk markers
Wang, M.-Y., Yu, X., Lee, Y., McCorkle, S. K., Clark, G. O., Strowig, S. M., Unger, R. H., & Raskin, P. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.08.008 · Cited by 38
Self-citationZhou, J., Bai, L., Wang, Y., & Yang, J. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12761 · Cited by 37
The Three Ds of Transcription Activation by Glucagon: Direct, Delayed, and Dynamic
Goldstein, I., & Hager, G. L. (2017) · Endocrinology · doi:10.1210/en.2017-00521 · Cited by 36
“signaling are the principal events driving diabetes (18).”
BackgroundGlucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling
Galsgaard, K. D., Winther-Sørensen, M., Pedersen, J., Kjeldsen, S. A. S., Rosenkilde, M. M., Wewer Albrechtsen, N. J., & Holst, J. J. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00410.2018 · Cited by 35
“To determine the inhibitory potency of GRA (25-2648), we tested its ability to inhibit glucagon-induced cAMP production using COS-7 cells transiently transfected with the mouse glucagon receptor or the mouse glucagon-like peptide 1 (GLP-1) receptor.”
BackgroundMethodBanerjee, S., Ghoshal, S., Stevens, J. R., McCommis, K. S., Gao, S., Castro‐Sepúlveda, M., Mizgier, M. L., Clemence, G., Kumar, K. G., Galgani, J. E., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014381 · Cited by 38
“This facet of type 2 diabetes has been attributed to insulin resistance in hepatocytes (83, 84) and hyperglucagonemia resulting from dysregulation of pancreatic a-cells (85).”
BackgroundUse of DREADD Technology to Identify Novel Targets for Antidiabetic Drugs
Wang, L., Zhu, L., Meister, J., Bone, D. B. J., Pydi, S. P., Rossi, M., & Wess, J. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-121042 · Cited by 38
Kobayati, A., Haidar, A., & Tsoukas, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14637 · Cited by 39
“Traditionally, glucagon has long been undervalued in the regulation of glucose homeostasis.(16) Above all, since mechanisms involved with physiological glucagon signalling are still in question, the dysregulation that occurs in a state of failing β cells remains difficult to comprehend.”
Williams, M. J., Wiemerslage, L., Gohel, P., Kheder, S., Kothegala, L., & Schiöth, H. B. (2016) · Endocrinology · doi:10.1210/en.2015-2006 · Cited by 37
“This speaks against the glucagonocentric idea of diabetes, which states that inhibition of glucagon is sufficient to rescue diabetic phenotypes (59).”
BackgroundPierzynowski, S. G., Gregory, P. C., Filip, R., Woliński, J., & Pierzynowska, K. G. (2018) · Nutrition and Diabetes · doi:10.1038/s41387-018-0062-9 · Cited by 35
Wu, G., Zhang, L., Li, T., Zuniga, A., Lopaschuk, G. D., Li, L., Jacobs, R. L., & Vance, D. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.415117 · Cited by 38
“Activation of Hepatic Glucagon Receptor Contributes to Choline-induced Glucose and Insulin Intolerance in Pemt / Mice Fed theHFHCDiet—Glucagon signals through glucagon receptors, which have a crucial role in mediating hyperglycemia in diabetes (19, 20).”
BackgroundInhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor
Mukund, S., Shang, Y., Clarke, H. J., Madjidi, A., Corn, J. E., Kates, L., Kolumam, G. A., Chiang, V., Luis, E., Murray, J. M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.496984 · Cited by 38
“An inappropriate increase in glucagon levels drives excess hepatic glucose output and contributes to hyperglycemia in type 2 diabetes (31).”
BackgroundBrun, P., Wongsiriroj, N., & Blaner, W. S. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2015.09.03 · Cited by 40
“This observation is consistent with the “glucagon hypothesis” of Unger and Cherrington (40) which proposes that glucagon is the proximal modulator of blood glucose in diabetes.”
ResultBrain–body communication in metabolic control
Furlan, A., & Petrus, P. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.08.014 · Cited by 37
“The overstimulated β-cells eventually perish, while α-cells continue to stimulate hepatic gluconeogenesis in the fed state, further contributing to hyperglycemia [25].”
BackgroundIordan, L., Gaiţă, L., Timar, R. Z., Avram, V. F., Sturza, A., & Timar, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137057 · Cited by 37
Demant, M., Bagger, J. I., Suppli, M. P., Lund, A., Gyldenløve, M., Hansen, K. B., Hare, K. J., Christensen, M., Sonne, D. P., Holst, J. J., et al. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0066 · Cited by 38
“10 Over the years, hyperglucagonemia has increasingly been recognized as a therapeutic target in patients with T2D 11,12 and the important role of hyperglucagone-mia in the pathophysiology of T2D has been confirmed in several studies, most clearly in recent studies employing glucagon receptor…”
Cilvik, S. N., Wesolowski, S. R., Anthony, R. V., Brown, L. D., & Rozance, P. J. (2021) · The Journal of Physiology · doi:10.1113/jp281288 · Cited by 41
The physiological basis of insulin therapy in people with diabetes mellitus
Bolli, G. B., Porcellati, F., Lucidi, P., & Fanelli, C. G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108839 · Cited by 42
Glucagon, cyclic AMP, and hepatic glucose mobilization: A half‐century of uncertainty
Rodgers, R. L. (2022) · Physiological Reports · doi:10.14814/phy2.15263 · Cited by 38
“…of glucagon’s central role in the etiology of diabetes (Burcelin et al., 1996; Johnson et al., 1982; Lee et al., 2012; Patil et al., 2020; Unger & Cherrington, 2012; Wewer Albrechtsen et al., 2019), resolving persistent uncertainties and establishing its true mechanism of action in…”
BackgroundÖzcan, L., Xu, X., Deng, S., Ghorpade, D. S., Thomas, T. A., Cremers, S., Hubbard, B. K., Serrano‐Wu, M. H., Gaestel, M., Landry, D. W., et al. (2015) · Diabetes · doi:10.2337/db14-1945 · Cited by 36
“Excessive hepatic glucose production (HGP) is a key defect found in T2D (2), and it is driven in large part by chronic hyperglucagonemia coupled with insufficient hepatic insulin action (3,4).”
BackgroundDapagliflozin suppresses glucagon signaling in rodent models of diabetes
Wang, M.-Y., Yu, X., Lee, Y., McCorkle, S. K., Chen, S., Li, J., Wang, Z. V., Davidson, J. A., Scherer, P. E., Holland, W. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705845114 · Cited by 35
“In addition, there is a large and growing literature showing that lowering blood glucose levels in diabetes requires the blunting of endogenous glucose production stimulated by glucagon (10, 11).”
BackgroundSelf-citationBen-Zvi, D., Barrandon, O., Hadley, S., Blum, B., Peterson, Q. P., & Melton, D. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513872112 · Cited by 34
Interleukin-6 amplifies glucagon secretion: coordinated control via the brain and pancreas
Barnes, T. M., Otero, Y. F., Elliott, A. D., Locke, A. D., Malabanan, C. M., Coldren, A., Briššová, M., Piston, D. W., & McGuinness, O. P. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00343.2014 · Cited by 35
Grubelnik, V., Markovič, R., Lipovšek, S., Leitinger, G., Gosak, M., Dolenšek, J., Valladolid-Acebes, I., Berggren, P.-O., Stožer, A., Perc, M., et al. (2020) · Royal Society Open Science · doi:10.1098/rsos.191171 · Cited by 32
Shen, N., Jiang, S., Lu, J., Yu, X., Lai, S., Zhang, J., Zhang, J.-L., Tao, W.-W., Wang, X., Xu, N., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.10.016 · Cited by 35
“5,14 As a hormone that regulates blood glucose levels, glucagon is most effective in promoting hepatic gluconeogenesis, which contributes to the abnormally increased endogenous glucose production in type 2 diabetes.”
BackgroundTanday, N., Irwin, N., Moffett, R. C., Flatt, P. R., & O'Harte, F. P. M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14177 · Cited by 35
“The role of excess glucagon in contributing to the hyperglycaemia of diabetes is well established.(42) In the present study, the benefits of pGlu(Lys(8)Glu-PAL)apelin-13 amide can be partially explained by the suppression of circulating glucagon in both HFD-fed and STZ-induced diabetic mice, probably associated with t…”
BackgroundZhang, Y., Wang, T., Hu, X., & Chen, G. (2021) · Journal of Medicinal Food · doi:10.1089/jmf.2020.0147 · Cited by 33
“81 Insulin is produced and secreted from pancreatic b -cells of Langham.”
Function of seipin: New insights from Bscl2/seipin knockout mouse models
Dollet, L., Magré, J., Cariou, B., & Prieur, X. (2013) · Biochimie · doi:10.1016/j.biochi.2013.06.022 · Cited by 34
“Interestingly, leptin is also able to improve glucose homeostasis due to a powerful suppression of glucagon secretion [54].”
BackgroundNiwano, F., Hiromine, Y., Noso, S., Babaya, N., Ito, H., Yasutake, S., Matsumoto, I., Takeyama, Y., Kawabata, Y., & Ikegami, H. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12799 · Cited by 33
Albrechtsen, N. J. W., Kuhre, R. E., Hornburg, D., Jensen, C. Z., Hornum, M., Dirksen, C., Svane, M. S., Gasbjerg, L. S., Jørgensen, N. B., Gabe, M. N., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.034 · Cited by 31
“However, the extent to which molecular heterogeneity is normally seen and whether it is involved in diabetes and/or other metabolically related diseases are unknown (Unger and Cherrington, 2012).”
BackgroundGlucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells
Armour, S. L., Frueh, A., Chibalina, M. V., Dou, H., Argemi‐Muntadas, L., Hamilton, A., Katzilieris‐Petras, G., Carmeliet, P., Davies, B., Möritz, T., et al. (2023) · Diabetes · doi:10.2337/db23-0056 · Cited by 34
Meek, T. H., Dorfman, M. D., Matsen, M. E., Fischer, J. D., Cubelo, A., Kumar, M. R., Taborsky, G. J., & Morton, G. J. (2015) · Diabetes · doi:10.2337/db14-1562 · Cited by 34
“Collectively, these data support the hypothesis that hyperglucagonemia plays a key role in driving diabetic hyperglycemia and consequently that suppressing glucagon is of therapeutic value in diabetes treatment (3).”
BackgroundInfluentialArum, O., Boparai, R. K., Saleh, J. K., Wang, F., Dirks, A. L., Turner, J. G., Kopchick, J. J., Liu, J., Khardori, R. K., & Bartke, A. (2014) · Aging Cell · doi:10.1111/acel.12262 · Cited by 31
“Very interesting new data are positioning the a-cells central in the development of types I and II diabetes mellitus (Unger & Orci, 2010; Habener & Stanojevic, 2012; Unger & Cherrington, 2012).”
BackgroundHuang, W. Q., Guo, J. H., Zhang, X., Yu, M., Chung, Y. W., Ruan, Y. C., & Chan, H. C. (2017) · Endocrinology · doi:10.1210/en.2017-00282 · Cited by 31
“also impaired or absent in patients with type 1 and type 2 diabetes mellitus (5, 66, 67).”
BackgroundChronic fractalkine administration improves glucose tolerance and pancreatic endocrine function
Riopel, M., Seo, J. B., Bandyopadhyay, G. K., Li, P., Wollam, J., Chung, H., Jung, S., Murphy, A. N., Wilson, M. E., de Jong, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94330 · Cited by 32
“In T2DM, insulin resistance potentiates α cell glucagon secretion and hepatic glucagon action, which stimulates hepatic glucose production (7, 8).”
BackgroundPPP1R3C mediates metformin-inhibited hepatic gluconeogenesis
Ji, X., Wang, S., Tang, H., Zhang, Y., Zhou, F., Zhang, L., Zhu, Q., Zhu, K., Liu, Q., Liu, Y., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.002 · Cited by 34
Hawkes, C. P., Lado, J. J., Givler, S., & León, D. D. D. (2018) · JIMD Reports · doi:10.1007/8904_2018_140 · Cited by 32
“both of which can be used for gluconeogenesis [reviewed in (Unger and Cherrington 2012)].”
BackgroundGlucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism
Zhang, L., Yao, W., Xia, J., Wang, T., & Huang, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081885 · Cited by 32
“Multiple research studies have proven that metabolic disorders accompany an increase in plasma glucagon concentration [20,142].”
BackgroundClinical Presentation and Diagnostic Approach to Hypoglycemia in Adults Without Diabetes Mellitus
Palani, G., Stortz, E., & Moheet, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2022.11.010 · Cited by 29
Parker, J., Briden, L., & Gersh, F. L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124021 · Cited by 41
Neumann, U. H., Ho, J. S. S., Mojibian, M., Covey, S. D., Charron, M. J., & Kieffer, T. J. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.014 · Cited by 29
“Recent evidence suggests that glucagon itself causes the lethal catabolic consequences of insulin deficiency [14].”
BackgroundCell Autonomous Dysfunction and Insulin Resistance in Pancreatic α Cells
Honzawa, N., Fujimoto, K., & Kitamura, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153699 · Cited by 33
“These reports indicate that glucagon plays a more important role than insulin in increasing blood glucose levels and support the “glucagonocentric hypothesis” proposed in 2012 [13].”
Soluble CD137 Ameliorates Acute Type 1 Diabetes by Inducing T Cell Anergy
Itoh, A., Ortiz, L. B., Kachapati, K., Wu, Y., Adams, D., Bednar, K. J., Mukherjee, S., Chougnet, C. A., Mittler, R. S., Chen, Y., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02566 · Cited by 29
Cullen, K. S., Al‐Oanzi, Z. H., O'Harte, F. P. M., Agius, L., & Arden, C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.02.006 · Cited by 29
“The present evidence that glucagon antagonises the action of elevated glucose on translocation of glucokinase from the nucleus and binding to PFK2/FBPase2 in the cytoplasm adds a new perspective to the acute control of glucokinase activity and shows that absolute or relative glucagon excess as occurs in diabetes [3] i…”
BackgroundInfluentialInsulin-and-Glucagon Artificial Pancreas Versus Insulin-Alone Artificial Pancreas: A Short Review
Haidar, A. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0097 · Cited by 30
Αλεξιάδου, Κ., Cuenco, J., Howard, J., Albrechtsen, N. J. W., Ilesanmi, I., Kamocka, A., Tharakan, G., Behary, P., Bech, P., Ahmed, A., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001076 · Cited by 30
Lundqvist, M., Almby, K. E., Wiklund, U., Abrahamsson, N., Kamble, P. G., Pereira, M. J., & Eriksson, J. W. (2020) · Diabetologia · doi:10.1007/s00125-020-05332-z · Cited by 31
Nakashima, K., Kaneto, H., Shimoda, M., Kimura, T., & Kaku, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-21751-w · Cited by 32
A Magnetic Dynamic Microbiointerface with Biofeedback Mechanism for Cancer Cell Capture and Release
Tian, X., Sha, X., Feng, Y., Duan, Y., Dong, M., Liu, L., & Pan, G. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b13140 · Cited by 28
Abnormal regulation of glucagon secretion by human islet alpha cells in the absence of beta cells
Liu, W. X., Kin, T., Ho, S., Dorrell, C., Campbell, S. R., Luo, P., & Chen, X. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.018 · Cited by 29
Zhao, S., Wang, Z., Qing, P., Li, M., Liu, Q., Pang, X., Wang, K., Gao, X., Zhao, J., & Wu, Y. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02355-3 · Cited by 30
“Fourth, excessive and inappropriate use of insulin, which may result in hypoglycemia, can further induce insulin resistance by stimulating the secretion of counter-regulatory hormones, mainly glucagon, along with catecholamines, cortisol, and growth hormone [32, 33].”
BackgroundNovel Insights into M3 Muscarinic Acetylcholine Receptor Physiology and Structure
Kruse, A. C., Li, J., Hu, J., Kobilka, B. K., & Wess, J. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-0127-0 · Cited by 30
“Taken together, these data strongly suggest that approaches aimed at enhancing signaling through β-cell M3Rs might become therapeutically useful for the treatment of type 2 diabetes (T2D).”
InfluentialChowdhury, S., Reeds, D. N., Crimmins, D. L., Patterson, B. W., Laciny, E., Wang, S., Tran, H. D., Griest, T. A., Rometo, D. A., Dunai, J., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00383.2013 · Cited by 29
Glucagon receptor signaling in metabolic diseases
Albrechtsen, N. J. W. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.016 · Cited by 29
“Whereas agonism of the glucagon receptor (GCGr) is commonly used for treatment of hypoglycemia in patients with type 1 diabetes [2,3] and potentially as a weight-lowering drug for obese individuals [4], antagonizing the GCGr on the other hand has been suggested a novel drug candidate for treatment of type 2 diabetes […”
Bi, Y., Tong, G. Y., Yang, H., Cai, M., Ma, J. H., Liang, J., Xin, B., Miao, H., Peng, Z., & Zhu, D. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2443 · Cited by 28
“As blood concentrations of glucagon are elevated in diabetes and glucagon is a major contributor to fasting hyperglycaemia [33], the hypoglycaemic efficacy of metformin can be in part attributable to their ability to reduced plasma glucagon level.”
BackgroundAre peptide conjugates the golden therapy against obesity?
Brandt, S. J., Kleinert, M., Tschöp, M. H., & Müller, T. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0264 · Cited by 27
Mouse models of peripheral metabolic disease
Xavier, G. D. S., & Hodson, D. J. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.009 · Cited by 30
Zonation of Pancreatic Acinar Cells in Diabetic Mice
Egozi, A., Halpern, K. B., Farack, L., Rotem, H., & Itzkovitz, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108043 · Cited by 26
“Systemic insulin concentrations are 174 pM (Garzilli and Itzkovitz, 2018) and are expected to be 100-fold higher locally within the peri-islet acinar cells (Unger and Cherrington, 2012).”
BackgroundGq signaling in α cells is critical for maintaining euglycemia
Liu, L., Dattaroy, D., Simpson, K. F., Barella, L. F., Cui, Y., Xiong, Y., Jin, J. J., König, G. M., Kostenis, E., ROMAN, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152852 · Cited by 28
“During times of fasting, circulating glucagon increases blood glucose levels primarily by activating hepatic glucagon receptors, resulting in enhanced hepatic glucose output (1-5).”
Yang, W., Liao, W., Li, X., Ai, W., Pan, Q., Shen, Z., Jiang, W. G., & Guo, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05916-5 · Cited by 28
Chen, W. K., Cui, W., Wu, J., Zheng, W., Sun, X., Zhang, J., Shang, H., Yuan, Y., Li, X., Wang, J., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155641 · Cited by 28
Xie, W., Ye, Y., Feng, Y., Xu, T., Huang, S., Shen, J., & Leng, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00476 · Cited by 26
“These findings highlighted the prospect of hepatic PDE3 for maintaining whole-body energy homeostasis and provided further information for the development of hepatic PDE3 as a potential target for T2DM therapeutics.”
BackgroundInfluentialStimulus-Secretion Coupling in Beta-Cells: From Basic to Bedside
Islam, M. S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12457-1_37 · Cited by 26
Asadi, F., & Dhanvantari, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.726368 · Cited by 28
Metadata
- Authors
- Unger, R. H., & Cherrington, A. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Unger, Roger H.
- ORCID
- Cherrington, Alan D.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 4-12
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3248306
- OpenAlex
- W2113278846
- Cited by
- 670
- References
- 100
- Citations by year
- 2026: 30 · 2025: 28 · 2024: 38 · 2023: 41 · 2022: 36 · 2021: 46 · 2020: 45 · 2019: 48 · 2018: 68 · 2017: 54 · 2016: 49 · 2015: 56 · 2014: 57 · 2013: 48 · 2012: 26
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Amylin Pharmaceuticals
- University of Texas Southwestern Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, hyperglucagonemia, diabetes pathophysiology, insulin deficiency, hepatic glucose production, ketogenesis, leptin, somatostatin, glucagon receptor, pancreatic beta cells, alpha cells, anti-insulin serum
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Glucagon, Humans, Insulin, Liver, Pancreas, Glycogenolysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.